US 20210253691A1

(19) United States

(12) Patent Application Publication

(10) Pub. No.: US 2021/0253691 A1

(43) Pub. Date: Aug. 19, 2021

SEOANE SUAREZ et al.

(54) **METHODS FOR IMPROVING RESPONSE TO ANTI-LIF ANTIBODY TREATMENT IN INDIVIDUALS WITH CANCER**

(71) Applicants: **MEDIMMUNE LIMITED**, Cambridge (GB); **FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL HEBRON**, Barcelona (ES); **FUNDACIO PRIVADA INSTITUCIO CATALANA DE RECERCA 1 ESTUDIS AVANCATS**, Barcelona (ES)

(72) Inventors: **Joan SEOANE SUAREZ**, Barcelona (ES); **Judit ANIDO FOLGUEIRA**, Barcelona (ES); **Robin Matthew HALLETT**, Toronto, ON (CA); **Peter Edward BAYLISS**, Toronto, ON (CA); **Ajitha JEGANATHAN**, Toronto, ON (CA); **Patricia Anne GIBLIN**, Boston, MA (US); **Isabel Huber RUANO**, Barcelona (ES); **Jeanne MAGRAM**, Boston, MA (US); **Monica Pascual GARCIA**, Barcelona (ES); **Ester Bonfill TEIXIDOR**, Barcelona (ES); **Ester Planas RIGOL**, Barcelona (ES)

(21) Appl. No.: **17/252,482**

(22) PCT Filed: **Jun. 17, 2019**

(86) PCT No.: **PCT/IB2019/000806**

§ 371 (c)(1),
(2) Date: **Dec. 15, 2020**

(30) **Foreign Application Priority Data**

Jun. 18, 2018 (EP) 18382431.7
Feb. 22, 2019 (EP) 19382131.1

Publication Classification

(51) **Int. Cl.**
C07K 16/24 (2006.01)
A61P 35/00 (2006.01)
G01N 33/574 (2006.01)

(52) **U.S. Cl.**
CPC ***C07K 16/244*** (2013.01); *A61K 2039/505* (2013.01); ***G01N 33/57488*** (2013.01); ***A61P 35/00*** (2018.01)

(57) **ABSTRACT**

Described herein are methods of selecting and treating patients likely to respond to treatment with an anti-LIF antibody.

Specification includes a Sequence Listing.